Pidotimod vs HD5
Head-to-head comparison of Pidotimod (3-L-Pyroglutamyl-L-Thiazolidine-4-Carboxylic Acid) and HD5 (Human Alpha-Defensin 5) — benefits, dosing, side effects, research data, and where to buy.
| Property | Pidotimod | HD5 |
|---|---|---|
| Category | Immune Support | Immune Support |
| Full Name | 3-L-Pyroglutamyl-L-Thiazolidine-4-Carboxylic Acid | Human Alpha-Defensin 5 |
| Molecular Weight | 244.27 Da | 3708 Da |
| Half-Life | 3-4 h | Minutes to hours; protease-sensitive |
| Amino Acids | 2 | 32 |
| Typical Dose | 400-800 mg/day | Research use only; no approved human dose |
| Route | Oral | Oral-local gut / Research parenteral |
| Purity | ≥98% | ≥98% |
| Studies Count | 200 | 260 |
| Research Status | Clinical | Pre-clinical |
Pidotimod Benefits
- ✓oral-immune-support
- ✓respiratory-infection-adjunct
- ✓innate-immunity
- ✓adaptive-immunity-support
HD5 Benefits
- ✓gut mucosal defense
- ✓antimicrobial activity
- ✓microbiome balance support
- ✓barrier integrity support
Pidotimod Dosing
400 mg PO BID|typically 15-30 days|repeated seasonal cycles in studies
HD5 Dosing
0.1–10 µM in vitro|1–5 mg/kg in animal models|No established human dose
Pidotimod Side Effects
- ⚠nausea
- ⚠diarrhea
- ⚠rash
HD5 Side Effects
- ⚠protease sensitivity
- ⚠potential epithelial irritation at high concentrations
- ⚠unknown systemic safety
Research Overview
Pidotimod
Pidotimod has human data in recurrent infections, especially where immune stimulation or reduced infection frequency is the target. Published work commonly reports improvements in phagocyte function, mucosal defense, and fewer respiratory infection episodes.
HD5
HD5 has been widely studied in intestinal innate immunity, particularly for its role in defending crypts against bacterial invasion. Preclinical literature supports activity against multiple microbes and links altered HD5 biology with gut barrier dysfunction.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.